Systematic review of efficacy and safety of Ginkgo biloba extract 50 in treatment of ischemic stroke.
10.19540/j.cnki.cjcmm.20210519.501
- Author:
Ying-Jie GUAN
1
;
Si-Hong YANG
1
;
Xue BAI
1
;
Wen-Jing CHANG
1
;
Wei CHEN
1
Author Information
1. Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine Beijing 100029, China.
- Publication Type:Systematic Review
- Keywords:
Ginkgo biloba extract 50(GBE50);
ischemic stroke;
randomized controlled trial(RCT);
systematic review
- MeSH:
Brain Ischemia/drug therapy*;
Ginkgo biloba;
Humans;
Ischemic Stroke;
Multicenter Studies as Topic;
Plant Extracts;
Stroke/drug therapy*
- From:
China Journal of Chinese Materia Medica
2021;46(22):5977-5986
- CountryChina
- Language:Chinese
-
Abstract:
The present study aimed to systematically evaluate the efficacy and safety of Ginkgo biloba extract 50(GBE50) in the treatment of ischemic stroke. The databases including CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, and Cochrane Library were searched for randomized controlled trial(RCT) of GBE50 for the treatment of ischemic stroke reported between database inception and May 2020. The methodological quality of the included RCTs was evaluated via the Cochrane risk of bias tool. The RevMan 5.4 was used for Meta-analysis. Sixteen RCTs were included, involving 1 615 patients with acute ischemic stroke. Most of the included RCTs reported the methods of random sequence generation, but only two performed the concealment of random sequence. All RCTs failed in blinding. Two RCTs reported the information of cases lost to follow-up and drop-outs. Since the number was small, the baselines of groups remained balanced. All RCTs reported key outcomes of ischemic stroke, which made selective reporting bias in a low risk. Meta-analysis results revealed that GBE50 combined with routine therapies could effectively lower the score of the National Institutes of Health stroke scale(NIHSS) and restore cognitive function and daily activity in ischemic stroke patients. Compared with routine therapies, the combination is advantageous in treating patients with ischemic stroke. However, high-quality multicenter RCTs with large sample sizes are still required for verification.
